Literature DB >> 6328975

Serologic evidence for widespread infection with La Crosse and St. Louis encephalitis viruses in the Indiana human population.

P R Grimstad, C L Barrett, R L Humphrey, M J Sinsko.   

Abstract

The vast under-reporting of La Crosse virus and St. Louis encephalitis virus infections in Indiana residents was evident when numerous inapparent infections were detected retrospectively using serum dilution neutralization analyses of serum obtained in November 1978-April 1979 from 10,208 persons (0.2% of the state's population). An antibody prevalence rate of 3.6% to St. Louis encephalitis virus was detected in the sample population as a whole, with rates as high as 13.2% for residents of individual counties. The estimated average annual rate of infection for the whole population was 0.32%. The antibody prevalence to La Crosse virus in the sample population as a whole was 2.3%, with rates ranging up to 12.5% for residents of individual counties. The estimated average annual rate of infection for the whole population was 0.29%. The epidemiologic behavior of the two viruses was quite different. Age-specific antibody prevalence for St. Louis encephalitis virus indicated a pattern of endemic infection existed in the population as a whole; antibody prevalence rose as the population aged. However, many other infections apparently occurred during the 1975 and earlier epidemics. Age-specific antibody prevalence for La Crosse virus indicated a typical pattern of endemic infection was present. The antibody prevalence to La Crosse virus was best described by the Poisson distribution and that of St. Louis encephalitis virus by the negative binomial distribution. These data support the hypothesis that St. Louis encephalitis virus primarily produces intermittent epidemics in the Midwest while La Crosse virus produces continuous seasonal endemic infections. However, evidence suggestive of a low level of interepidemic St. Louis encephalitis virus infection in the population was also obtained. Computer-drawn synagraphic mapping view "maps" of regional antibody prevalence rates demonstrated the existence of distinct foci of infection for each virus in the human population.

Entities:  

Mesh:

Year:  1984        PMID: 6328975     DOI: 10.1093/oxfordjournals.aje.a113814

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  11 in total

1.  Characterization of La Crosse virus RNA in autopsied central nervous system tissues.

Authors:  L J Chandler; M K Borucki; D K Dobie; L P Wasieloski; W H Thompson; C B Gundersen; K Case; B J Beaty
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

2.  Neuroattenuated bunyavirus variant: derivation, characterization, and revertant clones.

Authors:  M J Endres; A Valsamakis; F Gonzalez-Scarano; N Nathanson
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

Review 3.  Innate immune response to La Crosse virus infection.

Authors:  Katherine G Taylor; Karin E Peterson
Journal:  J Neurovirol       Date:  2013-07-12       Impact factor: 2.643

4.  La Crosse Virus Infection of Human Keratinocytes Leads to Interferon-Dependent Apoptosis of Bystander Non-Infected Cells In Vitro.

Authors:  Maria A Cruz; Griffith D Parks
Journal:  Viruses       Date:  2020-02-25       Impact factor: 5.048

5.  The incidence risk, clustering, and clinical presentation of La Crosse virus infections in the eastern United States, 2003-2007.

Authors:  Andrew D Haddow; Agricola Odoi
Journal:  PLoS One       Date:  2009-07-03       Impact factor: 3.240

6.  Lack of evidence for zoonotic transmission of Schmallenberg virus.

Authors:  Chantal Reusken; Cees van den Wijngaard; Paul van Beek; Martin Beer; Ruth Bouwstra; Gert-Jan Godeke; Leslie Isken; Hans van den Kerkhof; Wilfrid van Pelt; Wim van der Poel; Johan Reimerink; Peter Schielen; Jonas Schmidt-Chanasit; Piet Vellema; Ankje de Vries; Inge Wouters; Marion Koopmans
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

7.  La Crosse Virus Disease in the United States, 2003-2019.

Authors:  Grace M Vahey; Nicole P Lindsey; J Erin Staples; Susan L Hills
Journal:  Am J Trop Med Hyg       Date:  2021-07-19       Impact factor: 3.707

8.  Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes.

Authors:  Richard S Bennett; David R Ton; Christopher T Hanson; Brian R Murphy; Stephen S Whitehead
Journal:  Virol J       Date:  2007-05-08       Impact factor: 4.099

9.  Assessing risk in focal arboviral infections: are we missing the big or little picture?

Authors:  Andrew D Haddow; Carl J Jones; Agricola Odoi
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

Review 10.  Throw out the Map: Neuropathogenesis of the Globally Expanding California Serogroup of Orthobunyaviruses.

Authors:  Alyssa B Evans; Karin E Peterson
Journal:  Viruses       Date:  2019-08-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.